Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Published:2016-10 Issue:10 Volume:38 Page:2265-2276
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Heise Tim,Jordan Jens,Wanner Christoph,Heer Martina,Macha Sreeraj,Mattheus Michaela,Lund Søren S.,Woerle Hans J.,Broedl Uli C.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012

2. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications;Gerich;Diabet Med,2010

3. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes;List;Diabetes Care,2009

4. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects;Ferrannini;Nat Rev Endocrinol,2012

5. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Häring;Diabetes Care,2014

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials;Advances in Therapy;2024-05-21

2. Type 2 diabetes patients requiring empagliflozin in Southeast of Iran: Frequency and guideline adherence (2022–2023);Hipertensión y Riesgo Vascular;2024-04

3. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes;JAMA Internal Medicine;2024-03-01

4. Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease;Frontiers in Endocrinology;2023-12-20

5. Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study;Journal of Clinical Medicine;2023-11-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3